Antibody News and Research

RSS
An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Further Reading

Portable, microchip-based test for diagnosing type-1 diabetes

Portable, microchip-based test for diagnosing type-1 diabetes

HIV detected in Mississippi baby after apparent cure

HIV detected in Mississippi baby after apparent cure

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

MIIR partners with international biosciences to develop potential anti-cancer drugs

MIIR partners with international biosciences to develop potential anti-cancer drugs

HD Biosciences and MIIR partner to co-develop potential anti-cancer drugs

HD Biosciences and MIIR partner to co-develop potential anti-cancer drugs

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Pharmalink’s core patents for Nefecon issued in United States, Europe, China and Hong Kong

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Novel cancer immunotherapy for dogs could benefit humans as well

Novel cancer immunotherapy for dogs could benefit humans as well

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Researchers discover a way to restore corneal surface

Researchers discover a way to restore corneal surface

Researchers take major step forward in understanding causes of CRPS

Researchers take major step forward in understanding causes of CRPS

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

Australian immunologists uncover additional role for antibody-making 'B cells'

Australian immunologists uncover additional role for antibody-making 'B cells'

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Prophage autologous cancer vaccine extends survival in patients with newly diagnosed GBM

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

A*STAR scientists pioneered a molecular connection between obesity and diabetes

A*STAR scientists pioneered a molecular connection between obesity and diabetes

Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.